Azathioprine immunosuppression and disease modification in parkinson’s disease (aza- pd): a randomised double- blind placebo- controlled phase ii trial protocol

HIGHLIGHTS

• who: Azathioprine immunosuppression and colleagues from the Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK have published the article: Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA- PD): a randomised double- blind placebo- controlled phase II trial protocol, in the Journal: BMJ Open 2020;10:e040527. of /2020/
• what: The authors propose that direct suppression of the peripheral immune system is an alternative, highly relevant therapeutic strategy that has not been tested in clinical trials to date. The trial aims to demonstrate ‘proof of mechanism' by evaluating the impact of azathioprine on . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.